Neurogene Inc. — Director's Dealing 2015

Aug 14, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AQUINOX PHARMACEUTICALS, INC (AQXP)
CIK: 0001404644
Period of Report: 2015-08-12

Reporting Person: MacKenzie Lloyd (VP Technical Operations)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-08-12	Common Stock	M	7812	$5.76	Acquired	7812	Direct
2015-08-12	Common Stock	M	28075	$5.76	Acquired	35887	Direct
2015-08-12	Common Stock	S	35887	$18.67	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-08-12	Stock Option (Right to Buy)	$5.76	M	7812	Acquired	2020-06-10	Common Stock (7812)	Direct
2015-08-12	Stock Option (Right to Buy)	$5.76	M	28075	Acquired	2021-11-10	Common Stock (28075)	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.775 to $20.43. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price withinh the ranges set in this footnote.

F2: Fully vested.

F3: The shares subject to this option shall vest and become exercisable at a rate of twenty-five percent of the total number of shares underlying the options on the one-year anniversary of the vesting commencement date and 1/48th of the total number of shares underlying the options each monthly anniversary of the vesting commencement date thereafter for so long as the recipient of the option provides continuous service to the issuer, such that the total number of shares underlying the options shall be fully vested on the four-year anniversary of the vesting commencement date.